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Abstract
Background: This study investigates the associations between changes in serum Triglycerides (S-TG), -Urate (S-
Urate), and -Glucose (S-Glu) and changes in serum Calcium (S-Ca), -Magnesium (S-Mg), and -Phosphate (S-P) in
patients with type 2 diabetes compared with non-diabetic patients.
Methods: The analysis is based on data collected from a secondary prevention population of women and men
(W/M) at risk for cardiovascular disease (type 2 diabetes, 212/200; non-diabetes 968/703). The whole population (n
= 2083) had a mean age of 51.0 (9.7) years and was stratified for sex and according to type 2 diabetes or non-
diabetes. The patients were followed for, either half a year or one year and changes in risk factors were calculated
from follow-up to baseline, the time when patients were admitted to the health center. The pattern of
relationships was evaluated using a structural equation model.
Results: Higher S-TG and S-Glu but lower S-Urate was revealed at baseline in type 2 diabetes women and men as
compared to their counterparts, non-diabetes patients. Women with type 2 diabetes had higher S-Ca and lower S-
Mg than non-diabetes women. Changes in S-Glu were associated with changes in S-Ca (+), baseline S-Ca (+), and
S-Urate (-) in type 2 diabetes men. Changes in S-Urate were associated with changes in S-Mg (+) in type 2
diabetes women and non-diabetes men. In men with non-diabetes, changes in S-Glu were associated with
changes in S-Mg (-). In women with non-diabetes, changes in S-Glu were associated with changes in S-P (-) and
changes in S-Urate with changes in S-Ca (+).
Conclusion: With respect to metabolic disturbances in non-diabetes and the awareness of risk for type 2 diabetes,
changes in S-Glu and changes in S-Ca, S-Mg, and S-P should be considered as risk factors for cardiovascular
disease. Increased early detection and corrections of high S-Ca, low S-Mg, and S-P in obese patients may improve
their metabolism and reduce the risk of CVD in patients with type 2 diabetes.
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Background
Distinguishing between metabolic disturbances in obese
non-diabetic patients and type 2 diabetic patients provides
information on how obesity related risk factors-including
dyslipidemia, hyperglycemia, and hyperuricaemia-influ-
ence progression to type 2 diabetes. As magnesium is
involved in glucose intolerance and S-Mg and incidence of
type 2 diabetes are inversely associated, it is important to
consider whether the serum levels of magnesium are con-
nected to metabolic control [1]. The disposal rate of glu-
cose in diabetes was related to fasting plasma magnesium
concentrations after a standard glucose tolerance test [2].
Low serum magnesium may be a predictor of both meta-
bolic syndrome and type 2 diabetes [3]. Low serum levels
of phosphate are related to the risk of insulin resistance in
a healthy population [4]. With chronic hypophosphatemia,
the disturbance on post-receptor level indicates insulin
resistance [5]. An experimental study suggested that phos-
phate depletion causes a high level of intracellular Ca in
pancreatic beta cells, which inhibits ATP-production and
results in low insulin secretion [6]. Glucose loads induce
urinary excretion of both calcium and magnesium [7] due
to decreased resorption in the proximal tubule [8]. This
mechanism can be illustrated by the comparative effects
from diuretic drugs, which may result in magnesuria and
acidosis, reflected by an increased urinary excretion with
or without changes in S-Mg [9,10].
This study tests whether there is a link between
changes in serum Triglycerides (S-TG), -Urate (S-
Urate), and -Glucose (S-Glu) and changes in serum Cal-
cium (S-Ca), -Magnesium (S-Mg), or -Phosphate (S-P)
over time and identifies if and how any associations are
specific for either type 2 diabetes or the non-diabetes
condition after stratification for sex. We tested the fol-
lowing three hypotheses (Hn) using the SEM.
H1: Changes in S-TG are related to baseline values of,
and changes in, S-Ca, S-Mg, and S-P when controlling
for age, baseline values of S-TG, and baseline values of,
and changes in, S-Glu, BMI, SBP, and S-Chol.
H2: Changes in S-Urate are related to baseline values
of, and changes in, S-Ca, S-Mg, and S-P when control-
ling for age, baseline values of S-Urate, and baseline
values of, and changes in, S-Glu and BMI.
H3: Changes in S-Glu are related to baseline values of,
and changes in, S-Ca, S-Mg, and S-P when controlling
for age, baseline values of S-Glu, and baseline values of,
and changes in, BMI.
The changes over time were measured at different
time spans for different individuals at 0.5 or 1.0 years.
Methods
The Study Population
The study included 2083 patients (1180 women and
903 men) admitted to the Vindeln Health Center
between 1984 and 1996. The patients were referred
from primary care center and hospitals in the county
and admitted to the center in groups of 30 for a four-
week residential comprehensive activity: 64% were
hypertensive’s, 20% had type 2 diabetes, and 55% had a
BMI > 30. In addition to the main diagnosis, around
50% had a second subsidiary diagnosis and the preva-
lence of multiple risk factors resembling metabolic
syndrome were high. None of the patients included in
the non-diabetes population had registered reduced
glucose tolerance or type 2 diabetes. The characteris-
tics of the patient population are described in Table 1.
Of the 2083 patients at baseline, 744 were followed-up
after 0.5 year (35.7%) and 1339 after 1.0 year (64.3%).
The analysis is based on data collected on women and
men (W/M) at risk for cardiovascular disease (type 2
diabetes, 212/200; non-diabetes 968/703). Written
informed consent was obtained from the participants
of this study. The Ethical Committee of North Sweden
at the University of Umeå, Sweden, approved the pro-
tocol in November 22, 2006 (Dnr 05-177M). The study
has been registered as a sub study to the Lifestyle
intervention trial (no. ISRCTN79355192).
The Life Style Intervention Program
The education and rehabilitation program at Vindeln
Health Center (VHE-center) has been described earlier
[11,12]. A problem-based learning perspective was
established and the responsibility of planning and
executing the activities was shared between patients and
the staff. The staff consisted of a doctor, a nurse, phy-
siotherapists, a dietician, and other important support
staff.
During the first four weeks, 114 full-time hours were
dedicated to food preferences, selections, physical exer-
cise, and stress management. Half a year or one year
after the program, the activities were repeated during a
four-day revisit to the center. The objective of this fol-
low-up was to establish functioning groups as a source
to achieve changes and as a start for individual targets.
The main focus was to combat risk of future cardiovas-
cular disease (CVD). A refresher course was used to
reinforce and revise the “home program”.
Assessments of Physical and Biochemical Variables
On the second day after arriving to VHE-center, systolic
blood pressure (SBP; mmHg), body weight (kg), and
height (cm) were recorded and body mass index (BMI)
calculated (kg/m2). For every patient, a trained nurse
measured blood pressure using a semi-automatic
machine. Blood variables were analyzed on the serum
sample according to the following standard routine
methods at the Department of Clinical Chemistry, Uni-
versity Hospital, Umeå, Sweden.
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Serum glucose (S-Glu) was determined using a hexo-
kinase method (Boehringer Mannheim Diagnostica,
Mannheim, Germany) on either Hitachi 717 or Hitachi
911. Serum cholesterol (S-Chol) was determined using
an enzymatic method (Boehringer Mannheim Diagnos-
tica, Mannheim, Germany) on either Hitachi 705 or
Hitachi 717. Serum triglycerides (S-TG) were deter-
mined using enzymatic methods (Boehringer Mannheim
Diagnostica, Mannheim, Germany) on Hitachi 717.
Serum urate (S-Urate) was determined using an enzy-
matic Uricase method (Boehringer Mannheim Diagnos-
tica, Mannheim, Germany) on Hitachi 705 or Hitachi
717.
Serum calcium (S-Ca) was determined using a com-
plexometric method from Boehringer Mannheim on
SMA II (Technicon) and on Hitachi 717 (after 1989).
Up until 1989, serum magnesium was determined using
the atomabsorption technique; after 1989, serum magne-
sium was determined using a colorimetrically-complex
method with reagens from Boehring Mannheim on
Hitachi 717. Serum phosphate (S-P) was determined
using an ammonium-molybdate method (Boehringer
Mannheim Diagnostica, Mannheim, Germany) on a
Boehringer Mannheim (SMA II Technicon) and on
Hitachi 717 (after 1989).
Statistical Analysis
The study population was stratified according to sex and
the diagnosis type 2 diabetes or non-diabetes. Repeated
t-tests of differences in mean for nine variables at base-
line were performed for women with type 2 diabetes
compared to men with type 2 diabetes, for non-diabetes
women compared to non-diabetes men, for women with
type 2 diabetes compared to non-diabetes women and
for men with type 2 diabetes compared to non-diabetes
men.
The patients were followed for, either half a year or
one year and changes in risk factors were calculated
from follow-up to baseline, the time when patients were
admitted to the health center. Structural Equation Mod-
eling (SEM) was used to analyze the associations
between changes in S-TG, S-Urate, S-Glu, and change
in S-Ca, S-Mg, and S-P, with age, change in BMI, SBP,
and serum cholesterol and baseline values as controlling
variables (Figure 1). The model was estimated in one
step for each of the four patient groups using the Gen-
eralized Least Squares (GLS) method [13].
Imputations were done with values from later time
when available. Otherwise, average values were used for
missing values. T-tests and chi2-tests were used to test
for differences between patients with few relatively
many missing values (0-1 and 5-8, respectively) at fol-
low-up regarding sex, type 2 diabetes or non-diabetes,
BMI at baseline, and age at admittance. We found no
significant differences except for sex (p = 0.0443): 5% of
the women and 3% of the men had 5-8 missing (85
patients out of 2083). No missing values were evident
for the variables sex, age, and diagnosis (type 2 diabetes
or non-diabetes); the other variables had missing values
between 3% and 12%.
The changes over time were measured at different
time spans for different individuals over 0.5 to 1.0 year
and with imputations from 1.5, and 5 years. These dif-
ferences were adjusted using a time variable (t = time to
follow-up) in the equations. Model fit was tested with
chi2- and RMSEA-tests. For every analysis, we used SAS
version 9.2. (SAS Institute, Cary. NC). The figures were
drawn with AMOS version 18.
Table 1 Mean and standard deviation (sd) for baseline characteristics and variables included in the SEM.
Type 2 diabetes Non-diabetes Women vs women1 Men
vs
men2







Age, yrs 51.3 (11.3) 53.5 (8.8) 0.0232 50.6 (9.9) 50.7 (9.1) 0.8117 0.4226 0.0001
BMI, kg/m2 32.3 (5.6) 30.3 (4.5) < .0001 31.0 (5.7) 30.5 (4.9) 0.0447 0.0046 0.5246
SBP, mmHg 146 (19) 148 (19) 0.3778 146 (19) 149 (19) 0.0023 0.8778 0.3456
S-Chol, mmol/l 6.6 (1.3) 6.6 (1.5) 0.9024 6.7 (1.4) 6.7 (1.4) 0.6422 0.2132 0.2311
S-TG, mmol/l 2.8 (2.4) 3.2 (2.5) 0.0639 2.1 (1.2) 2.7 (2.0) < .0001 < .0001 0.0079
S-Glu, mmol/l 10.7 (4.6) 10.8 (4.6) 0.8787 5.3 (1.1) 5.4 (1.3) 0.0029 < .0001 < .0001
S-Urate, mmol/l 298 (80) 322 (84) 0.0036 316 (72) 384 (72) < .0001 0.0028 < .0001
S-Ca, mmol/l 2.37 (0.11) 2.34 (0.12) 0.0285 2.35 (0.10) 2.34 (0.09) 0.0063 0.0323 0.6119
S-Mg, mmol/l 0.78 (0.13) 0.81 (0.12) 0.0017 0.83 (0.12) 0.83 (0.13) 0.4164 < .0001 0.0610
S-P, mmol/l 1.05 (0.21) 0.97 (0.18) < .0001 1.05 (0.21) 0.96 (0.20) < .0001 0.9502 0.6015
Comparisons between type-2 diabetes and non-diabetes patients and for women with type 2 diabetes vs. women with non-diabetes and for men with type 2
diabetes vs. men with non-diabetes.
1/for comparisons between type 2 diabetes women and non-diabetes women
2/for comparisons between type 2 diabetes men and non-diabetes men
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Results
Baseline Data
A significantly higher S-TG and S-Glu levels and signifi-
cantly lower S-Urate levels were seen for both women
and men with type 2 diabetes compared to non-diabetes
women and men. Women with type 2 diabetes had
higher BMI and S-Ca and lower S-Mg than non-diabetes
women (Table 1).
Comparing women and men at baseline within each
diagnostic group reveals that women with type 2 dia-
betes had higher BMI, S-Ca, and S-P but lower S-Urate
and S-Mg compared to men with type 2 diabetes. Non-
diabetes women had lower SBP, S-TG, S-Glu, and S-
Urate but higher S-Ca and S-P as compared to men
with non-diabetes.
Changes in Common for the Four Groups
In all four sub-groups, changes in S-TG follow S-Chol
(+) changes after controlling for baseline values, age,
and changes in BMI and all the other metabolic vari-
ables included in the SEM (Table 2 and Figure 2, 3, 4,
5). In all four groups of patients, change in S-TG was
related to baseline levels of both S-Chol (+) and S-TG
(-), change in S-Urate was related to baseline S-Urate
(-), and change in S-Glu was related to baseline S-Glu
(-). After adjustments, no direct association was seen
between changes in S-TG and baseline values or to
changes in S-Ca, S-Mg, or S-P in any of the studied
groups (Table 2 and Figure 2, 3, 4, 5).
Diagnose Specific Associations
Change in S-Urate was directly associated with change
in BMI (+), age (+) and change in S-Mg (+) in type 2
diabetes women (Figure 2).
Change in S-Urate was associated with baseline S-Glu
and a change in S-Glu (-) in type 2 diabetes men (Figure
3). Change in S-Glu was directly related to baseline S-Ca
(+) and S-P (-) and to a change in S-Ca (+) in type 2
diabetic men with an indirect effect on both changes in
S-TG and changes in S-Urate (Figure 3).
In both women and men with non-diabetes, change in
S-TG was related to baseline BMI (+) and S-Glu (+) and
to changes in BMI (+) and changes in S-Glu (+) (Table
2 Figure 4 and 5). Change in S-Urate was related to
BMI (+) at baseline and to changes in BMI (+) (Table 3
Table 2 Estimated regression coefficients in SEM, with
changes in S-TG as endogenous variable, for type 2
diabetes and non-diabetes women and men.
Type 2 diabetes Non-diabetes
Women Men Women Men
Variables Par est. Par est. Par est. Par est.
Change in
S-TG
Age 0.015 -0.011 -0.001 -0.010
Baseline
BMI 0.012 0.036 0.017c 0.032a
SBP -0.007 -0.006 -0.001 -0.002
S-Chol 0.230 b 0.537c 0.108c 0.446 c
S-TG -0.515 c -0.424 c -0.468c -0.665 c
S-Glu -0.007 0.118 b 0.089 c 0.251 c
Change
BMI 0.065 -0.228b 0.054c 0.071 b
SBP -0.007 0.012 -0.001 -0.003
S-Chol 0.573 c 0.611 c 0.186 c 0.841 c
S-Glu 0.029 0.117 b 0.096 c 0.108a
Baseline
S-Ca -1.510 0.799 -0.021 0.819
S-Mg 0.292 -1.464 -0.253 0.086
S-P 0.523 -1.521 0.063 -0.453
Change
S-Ca 0.223 0.299 0.271 -0.375
S-Mg -1.431 -2.386 -0.370 -0.958
S-P 0.261 -1.231 0.189 -0.520
R2 0.6658 0.3798 0.4272 0.5548
At the bottom, R2 are presented.
a = p < 0.05; b = p < 0.01; c = p < 0.001
Figure 1 The Structural Equation Model estimated for women
with type 2 diabetes (X2 = 21.8, df = 19, p = 0.294, RMSEA =
0.027, p-close = 0.786); men with type 2 diabetes (X2 = 21.2, df
= 19, p = 0.324, RMSEA = 0.024, p-close = 0.7896); women
with non-diabetes (X2 = 79.2, df = 19, p < 0,0001, RMSEA =
0,057, p-close = 0,166); and men with non-diabetes (X2 = 59.9,
df = 19, p < 0.0001, RMSEA = 0.055, p-close = 0.266).
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Figure 2 Arrows indicate significant relations (p < 0.05) in the
Structural Equation Model for women with type 2 diabetes.
Figure 3 Arrows indicate significant relations (p < 0.05) in the
Structural Equation Model for men with type 2 diabetes.
Figure 4 Arrows indicate significant relations (p < 0.05) in the
Structural Equation Model for women with non-diabetes.
Figure 5 Arrows indicate significant relations (p < 0.05) in the
Structural Equation Model for men with non-diabetes.
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Figure 4 and 5). Change in S-Glu was related to BMI (+)
at baseline and to change in BMI (+) (Table 4 Figure 4
and 5).
In non-diabetic women, change in S-Urate was
directly related to age (+) and to a change in S-Ca (+),
and a change in S-Glu was directly associated with a
change in S-P (-), with an indirect effect on S-TG (Fig-
ure 4). In non-diabetic men, change in S-Glu was
directly related to age (+) and directly to change in S-
Mg (-), and a change in S-urate was directly related to
change in S-Mg (+) (Figure 5).
Gender Specific Results
In both type 2 diabetic women (Figure 2) and non-dia-
betic women (Figure 4) change in S-Urate was related
to Age (+) and to change in BMI (+).
In both, type 2 diabetic men (Figure 3) and non-dia-
betic men (Figure 5) change in S-TG was related to
baseline S-Glu (+) and to change in BMI (-) and S-Glu
(+).
Discussion
An association between the changes in S-TG, S-Urate,
and S-Glu and BMI at both baseline and with change in
BMI over time was shown in non-diabetic women and
men, and these changes were not evident in women and
men with type 2 diabetes except for an association
between change in S-Urate and BMI change in women
with type 2 diabetes. The strong association between
change in S-Urate and BMI, shown in the obese non-
diabetic condition in the present study, is a clinical find-
ing described in connection with obesity and the meta-
bolic syndrome [14]. The non-significant association,
between changes in S-Urate and BMI at baseline for
patients with type 2 diabetes, is an indication of the
importance, of separating non-diabetes and obesity
related metabolic disturbance from those within type 2
diabetes patients, in the assessment of CVD and mortal-
ity risk. Losing weight reduces CVD-risk, which, in the
case of obesity, is partly explained by less body fat and
reduced S-TG and S-Urate and improved S-Glu control.
In the present study, a change in S-Glu was associated
with a change in S-P (-) in non-diabetic women and
with change in S-Mg (-) for non-diabetic men. This
result could not have been due to weight loss as we
adjusted for this in the SEM. These inverse associations
had indirect effects on change in S-TG among non-dia-
betic patients. It has been postulated that the association
between blood lipids and S-Mg are different in type 2
diabetes compared to non-diabetes [15]; however, no
direct associations between changes in S-TG and
changes in the three electrolytes could be seen.
Table 3 Estimated regression coefficients in SEM, with
changes in S-Urate as endogenous variable, for type 2
diabetes and non-diabetes women and men.
Type 2 diabetes Non - diabetes
Women Men Women Men
Variables Par-est. Par-est Par est. Par est.
Change in
S-Urate
Age 1.273 c 0.097 0.785 c -0.145
Baseline
BMI 1.507 1.500 1.886 c 1.062a
S-Glu -1.333 -4.764 c 0.476 3.087
S-Urate -0.228 c -0.304 c -0.414 c -0.314 c
Change
BMI 4.122a 0.967 4.642 c 5.277c
S-Glu -1.050 -5.073 c 1.027 -1.335
Baseline
S-Ca 82.235 28.196 8.972 1.649
S-Mg 6.787 25.754 -6.680 22.986
S-P -1.801 14.872 3.186 6.592
Change
S-Ca 16.775 70.103 43.208a 22.217
S-Mg 133.5 b 52.535 30.075 50.062a
S-P 30.628 18.561 2.550 1.794
R 2 0.2225 0.2859 0.2959 0.2068
At the bottom, R2 are presented.
a = p < 0.05; b = p < 0.01; c = p < 0.001
Table 4 Estimated regression coefficients in SEM, with
changes in S-Glu as endogenous variable, for type 2
diabetes and non-diabetes women and men.
Type 2 diabetes Non - diabetes
Women Men Women Men
Variables Par est. Par est. Par est. Par est.
Change in
S-Glu
Age 0.003 -0.002 0,004 0.016 c
Baseline
BMI -0.020 -0.085 0.029 c 0.052 c
S-Glu -0.414 c -0.692 c -0.513 c -0.499c
Change
BMI 0.157 0.083 0.065c 0.078 c
Baseline
S-Ca 5.479 7.251b 0.853 -0.378
S-Mg 1.528 -1.234 0.097 -0.391
S-P -1.589 -3.507a 0.173 0.397
Change
S-Ca 2.725 6.785a 0.524 -0.287
S-Mg -1.297 -4.430 -0.482 -1.023 b
S-P 0.672 -2.775 -0.434a -0.151
R2 0.2225 0.5473 0.2320 0.2912
At the bottom R2 are presented.
a = p < 0.05; b = p < 0.01; c = p < 0.001
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A high S-Uric acid level in otherwise healthy indivi-
duals may be due to some oxidative stress and may pre-
dict type 2 diabetes [16]. In that study, high levels
preceded the development of glucose intolerance and
were not comparable to high S-Urate in type 2 diabetes.
The lower S-Urate at baseline in type 2 diabetes com-
pared with non-diabetes and the inverse relation between
changes in S-Urate and S-Glu in type 2 diabetes in our
study could be explained by an increased resorption in
proximal tubule and both insulin and S-Glu are involved
in this regulation [17,18]. Recently, Oda and Kawai
(2010) found that uric acid is positively associated with
metabolic syndrome but negatively associated with dia-
betes in Japanese men [19]. These findings have been
confirmed in a patient population where duration of type
2 diabetes, fasting blood glucose, and HbA1c were inver-
sely related to the level of serum uric acid [20]. High glu-
cose levels as indicated by HbA1c (a marker for the level
of glucose over time) could be used to identify risk for
diabetes [21]. Other metabolic markers (including using
uric acid as a marker for changes in S-glucose) will give
additional information about metabolic control. In pre-
diabetic women, hyperuricemia was positively associated
with level of S-Glucose [22].
In the present study, the inverse relation between
changes in S-Glu and S-Urate over a short time in type
2 diabetic men, not reported earlier, suggests a meta-
bolic disturbance of interest in understanding why high
S-Urate in some studies does not increase CVD risk.
Among women but not men with both type 2 diabetes
and non-diabetes, change in S-Urate was positively asso-
ciated with age.
Can changes in any of S-Ca, S-Mg, or S-P be linked to
the inverse relation between changes in S-Urate and
changes in S-Glu in type 2 diabetic men in the present
study? The results indicate that when S-Glu changes,
caused by S-Ca changes, an indirect and inverse effect
on S-Urate was revealed. This association was positive,
e.g., B-Glu increased with increasing S-Ca.
Changes in S-Glu were also associated with baseline S-
Ca in type 2 diabetic men, which further gives strength
to our hypothesis of links between energy metabolism
and the three electrolytes. In addition, women with type
2 diabetes had higher S-Ca than non-diabetic women at
baseline indicating some common disturbances in
women and men with type 2 diabetes. On the contrary,
S-Glu change was inversely related to baseline S-P in
men with type 2 diabetes, indicating that a high S-P
might cause a decrease in B-Glucose. With high S-P,
secretion of insulin is normalized and peripheral glucose
uptake improved [23]. These results indicate an involve-
ment of both S-Ca and S-P in achieving glucose control.
S-Ca may be released from the surface of the bones
and be responsible for the increase in glucose due to
low S-P levels, which stimulate bone resorption.
Whether an increase in calcium is a result from the dis-
turbed glucose handling or from other mechanisms is
not known, but it has been suggested that diabetic
patients should be checked for hypercalcemia at appro-
priate intervals [24]. A signaling pathway for the link
between energy metabolism and bone remodeling has
been presented [25]. The correlations revealed between
osteocalcin and insulin resistance might include changes
in both S-P and S-Ca, and it would have been interest-
ing to know if a high concentration of S-Ca together
with high S-Glu is associated with lack of osteocalcin.
The signaling pathway, with increase in leptin due to
obesity and decrease in osteocalcin, may help regulate,
primary or secondary, these ionic changes.
Earlier, we described that high S-Ca but low S-Mg
without involvement from S-P can predict all-cause
mortality in type 2 diabetes, although this is stronger for
men than for women [26]. Other studies also describe
high mortality with high S-Ca [27,28]. Women with type
2 diabetes had in addition to their lower S-Mg, signifi-
cantly higher S-Ca compared to men with type 2 dia-
betes and non-diabetic women at baseline. It has been
postulated that, parathyroid hormone mediates the
direct effects from phosphate, calcium, vitamin D, and
magnesium on metabolic syndrome in women but not
men [29]. The ionic involvement is important to high-
light as low S-Mg and low S-P and high S-Ca have
implications for CVD risk in type 2 diabetes with or
without disturbed glucose and urate metabolism.
It has been suggested that the metabolic disturbances
in type 2 diabetes causes hypomagnesaemia [30,31].
Women with type 2 diabetes might lose more S-Mg
than men do as indicated from low baseline values and
from the strong response from the change in magne-
sium on change in S-Urate. A change in S-Mg asso-
ciated with change in S-Urate, however, was also
revealed in non-diabetic men.
With a decrease in S-Glu and concomitantly increase
in S-Mg and decrease in S-Ca, the risk for CVD may be
reduced even though S-Urate increases. An increase in
S-Mg might have had an intracellular effect, which is
important to consider in risk level determination, related
to ischemia, catecholamine elevations, and insulin resis-
tance [32,33]. This indicates that it is not enough to
improve metabolic control with insulin or oral hypogly-
caemic agents: it is also important to reverse hypomag-
nesemia [34]. A supplementation with magnesium may
be needed to correct the low levels.
In conclusion
The metabolic disturbances in non-diabetes condition is
associated with changes in body weight, indicated from
the findings of this study, of changes in only non-
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diabetic women and men but not in type 2 diabetic
patients. In addition, changes in S-P (women) and S-Mg
(men) were associated with changes in S-Glu (+) in the
non-diabetic population. Thus, the low S-P in obesity
might disturb the regulation of S-Glu in non-diabetes.
This disturbance, in turn, might result in high S-Ca and
low S-Mg in type 2 diabetes, maybe the two missing
links in the study of CVD risk in this patient population.
These associations are strengthened by the result of an
association between changes in S-Urate and S-Mg (+) in
women with type 2 diabetes, which is associated with
change in S-Glu (-). In non-diabetics, low S-P should be
considered as a risk factor for type 2 diabetes, while low
S-Mg and high S-Ca should be considered as risk factors
for CVD in type 2 diabetic patients.
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